View Associated Notes
Category 6 - PATHOLOGY SERVICES
73076 - Additional Information
Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if:
(a) the cytology is associated with the detection of oncogenic human papillomavirus infection by:
(i) a test to which item 73070, 73071, 73074 or 73075 applies; or
(ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or
(b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or
(c) the cytology is associated with a test to which item 73074 applies; or
(d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or
(e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma
Fee: $46.00 Benefit: 75% = $34.50 85% = $39.10
(See para PN.0.22 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
Cervical and Vaginal Screening - (Items 73070 to 73076)
It is the responsibility of the treating healthcare practitioner to determine if the sample is being collected as part of the routine screening program under 73070 or 73071 or represents a sample falling under 73072 or 73074 or 73075 or 73076, and to indicate this on the request form. Unless a co-test is specifically requested, requiring the pathology laboratory to perform both a human papillomavirus (HPV) test and a liquid based cytology (LBC) test on the same specimen, for a clinician-collected sample, the pathology laboratory will by default perform an HPV test and then only undertake reflex LBC testing if oncogenic HPV (any type) is detected. The pathology laboratory will issue the HPV test result, the LBC test result and overall screening risk rating as a combined report as prescribed by the National Pathology Accreditation Advisory Council (NPAAC) Requirements for Laboratories reporting tests for the National Cervical Screening Program (NPAAC Requirements).
The test used for detecting oncogenic HPV must allow partial HPV genotyping to identify HPV16, HPV18 with or without HPV45 as well as meet the criteria for a population based screening test as prescribed by the NPAAC Requirements.
When used together, the self-collection device and the HPV test must meet the NPAAC Requirements, including the HPV test must be a polymerase chain reaction (PCR) test.
73070 applies to an HPV test on a cervical specimen for primary screening purposes and collected by a healthcare practitioner (or an accredited test provider under the supervision of a healthcare practitioner). 73071 applies to HPV tests for primary screening purposes requested by a healthcare practitioner (or an accredited test provider under the supervision of a healthcare practitioner) on a self-collected vaginal specimen. Tests for both 73070 and 73071 must be from an asymptomatic patient as part of routine five yearly screening recommended by the National Cervical Screening Program. The Health Insurance Act 1973 excludes payment of Medicare Benefits for health screening services except where Ministerial directions have been issued to enable benefits to be paid, this includes HPV testing that is performed in accordance with the policy of the National Cervical Screening Program (available at https://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program). This policy provides for a screening interval of five years for an asymptomatic patient commencing at 24 years and 9 months of age and for a patient aged between 70 to 74 years of age to cease cervical screening if the last test result is normal (i.e. low risk). A patient aged 75 years of age or older who has never had a cervical screening test or has not had one in the previous five years, may request a cervical screening test and be screened.
In accordance with the national policy for the National Cervical Screening Program, where oncogenic HPV (any type) is detected from a sample collected by a healthcare practitioner (73070), the pathology laboratory will conduct reflex LBC automatically under 73076 (a) without requiring an additional request by the treating healthcare professional. Where oncogenic HPV (non 16/18) is detected from a self-collected vaginal sample (73071), the participant will need to return to their healthcare practitioner for the collection of a cervical sample for LBC. The healthcare practitioner collected liquid based sample from the cervix that follows, can be claimed under 73076 (a) with a further request by the treating healthcare practitioner.
73072 applies to HPV tests where the specimen has been collected in accordance with the National Cervical Screening Program: Guidelines for the Management of Screen Detected Abnormalities, Screening in Specific Populations and Investigation of Abnormal Vaginal Bleeding (NCSP Clinical Guidelines) which provides for:
(a) an HPV test performed on a patient within a specific population suggestive of a higher risk of pre cancerous or cancerous cervical changes. HPV tests carried out in specific populations under Item 73072 should be in accordance with the NCSP Clinical Guidelines including:
(i) screening with a primary HPV test every 3 years for an immune-deficient patient; or
(ii) a single HPV test between 20 and 24 years of age could be considered by healthcare practitioners on a case by case basis for a patient who experienced first sexual activity at a young age (less than 14 years of age) and who has not received the HPV vaccine before sexual debut; or
(b) an HPV test performed for the follow up management of previously detected oncogenic HPV infection; or
(c) a co-test (HPV+LBC) for the investigation of symptoms of cervical cancer, most commonly abnormal vaginal bleeding; or
(d) co-test (HPV+LBC) for the management of a patient following treatment of high grade squamous intraepithelial lesions (HSIL) of the cervix as part of a ‘test of cure’ process performed at 12 months after treatment and annually thereafter, until receiving a negative co-test on two separate consecutive occasions, then the patient can return to routine five yearly screening. In accordance with the NCSP Clinical Guidelines this also applies to a patient undergoing follow up or post-treatment for a glandular abnormality as part of annual surveillance performed indefinitely; or
(e) a co-test (HPV+LBC) for the follow up management of glandular abnormalities; or
(f) a co-test (HPV+LBC) for screening a patient exposed to diethylstilbestrol (DES) in utero and daughters of patients exposed to DES in utero, if requested; or
(g) a co-test (HPV+LBC) for a patient previously treated for a genital tract malignancy.
A co-test requires both HPV and LBC tests to be performed irrespective of the HPV test result and so must be performed on a clinician collected cervical sample. In other HPV tests, LBC is only required if oncogenic HPV (any type) is detected; where oncogenic HPV (any type) has been detected in a liquid based sample from the cervix by a healthcare professional, the pathology laboratory will conduct LBC automatically without requiring an additional request. It is the intention of the National Cervical Screening Program where a co-test is requested or oncogenic HPV has previously been detected under this item, the LBC can be claimed under 73076 without requiring an additional request by the treating healthcare professional.
73074 applies to an HPV test on a vaginal vault specimen from a patient with past history of total hysterectomy, in accordance with the NCSP Clinical Guidelines which provides for:
(a) an HPV test for a patient who has no evidence of cervical pathology and the patient’s screening history is not available, performed at 12 months following a total hysterectomy and annually thereafter until a patient has two negative HPV tests (i.e. oncogenic HPV not detected) on two separate consecutive occasions and can be advised that no further testing is required; or
(b) a co-test (HPV+LBC) for a patient who has had a total hysterectomy, performed at 12 months following a total hysterectomy and annually thereafter until two consecutive co-tests are negative:
(i) if unexpected LSIL or HSIL is identified in the cervix at the time of total hysterectomy after completed ‘test of cure’ process; or
(ii) if the total hysterectomy was for treatment of high-grade cervical intraepithelial neoplasia in the presence of benign gynaecological disease; or
(iii) if the total hysterectomy was after histologically confirmed HSIL without Test of Cure and there is no cervical pathology; or
(c) indefinite co-testing (HPV+LBC) for a patient who has had a total hysterectomy, performed at 12 months after treatment and annually thereafter if the total hysterectomy was after adenocarcinoma in situ (AIS).
73075 applies to HPV tests repeated due to an unsatisfactory HPV test under 73070 or 73071 or 73072 or 73074.
73076 applies to a liquid-based cytology (LBC) test on a cervical or vaginal vault specimen:
(a) as part of a reflex test following detection of oncogenic HPV described in the national policy and NCSP Clinical Guidelines associated with items 73070 or 73071 or 73072 (a) or (b) or 73074 or 73075; or
(b) as part of a co-test described in the national policy and NCSP Clinical Guidelines under 73072 (c) or (d) or (e) of (f) or 73074; or
(c) where the previous specimen collected is unsatisfactory; or
(d) for the follow up management of a patient with a past history of total hysterectomy for endometrial adenocarcinoma.
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change